TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Cranberry and Prevention of UTI A Comprehensive Approach
Brief Summary: This study will determine whether cranberry juice is effective in reducing recurrent urinary tract infections (UTIs) in women who have had a UTI within the past year.


Options:
A: The primary outcome variable will be UTI incidence density, defined as the semi-annualized number of UTIs in each group, adjusted for susceptible time under observation. (six months)
B: Number of cases of asymptomatic bacteriuria
C: Time to onset of a first UTI within one year of treatment. (one year)
D: Rate of UTIs (6 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized, Double-Blind Trial to Assess the Safety and Relative Efficacy of CAIV-T Against Inactivated Influenza Vaccine in Children 6-59 Months of Age
Brief Summary: The primary objective of this study is to estimate the relative efficacy and assess the safety of CAIV-T compared to TIV.


Options:
A: The primary endpoint for efficacy is the first episode in the first season in a study child of a culture-confirmed influenza illness, caused by community-acquired subtypes antigenically similar to those contained in the vaccine.
B: The primary efficacy endpoint of this study is the relative efficacy of CAIV-T; compared to TIV against the incidence of culture-confirmed symptomatic influenza infection caused by community-acquired wild-type strains antigenically similar to those contained in the vaccine, occurring during the; influenza surveillance period and at least 14 days after the last required vaccination
C: Number of Subjects (Unprimed) 6 to <36 Months Age With Local and Systemic Reactions After Any Vaccination for All Seasons, Comparison of Adjuvanted Trivalent Influenza Vaccine (aTIV) and Flu Vaccine Control. (7 days post-vaccination); Percentage of Subjects (Unprimed) Aged 6 to <36 Months With Virus-Confirmed Influenza, Comparison of aTIV and Non-flu Vaccine Control (Men C/TBE Vaccine) (3 weeks after 2nd vaccination)
D: Laboratory-confirmed influenza infection. (up to 3 years)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Clinical Trial of Short Course Rifampin Versus INH for LTBI in Jail
Brief Summary: The purpose of this study is to determine whether an alternative drug, (rifampin) given daily, is better at treating tuberculosis (TB) and more tolerable than the usual drug treatment, isoniazid (INH). Study participants will include 972, TB infected, San Francisco Jail inmates, aged 18 or older. One group of volunteers will take INH two times a week for 9 months, and the other group will take rifampin daily for 4 months. Medication will be administered in jail and at the San Francisco TB Clinic if the volunteer is released from jail prior to completing the study. Participants will be seen daily for 4 months (rifampin group), and 2 times a week for 9 months (INH group) for directly observed therapy. Study procedures will include 5 symptom review visits and blood samples for lab testing. Follow-up will continue for each subject for five years after enrollment into the study.


Options:
A: Time to Development of Tuberculosis (TB) Disease or Death Among HIV-infected Children (Through to week 96); Time From Randomization to Development of TB Infection or Death Among Perinatally Exposed, HIV-uninfected Children (Through to week 96)
B: TB incidence (Jan 2003 to July 2011); Mortality (Jan 2003 to July 2011)
C: Number of Participants With Laboratory Test or Clinical Judgment Resulting in the Need to Stop Study Medication (up to one year)
D: to compare the compliance; to compare the side effects

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Financial Incentives for Smoking Cessation
Brief Summary: The purpose of this study is to test the effectiveness of financial incentives for increasing long-term smoking cessation rates among employees at General Electric worksites throughout the United States.


Options:
A: Biochemically verified smoking cessation rates at 6 months post-quit date
B: Smoking Behavior (Self-report Confirmed by Expired Breath CO) (8 week follow up); Urinary Cotinine (8 week follow-up)
C: Smoking Status at 6 Months (6 months after enrollment)
D: Biologically confirmed tobacco cessation (6 months)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Financial Incentives for Smoking Cessation
Brief Summary: The purpose of this study is to test the effectiveness of financial incentives for increasing long-term smoking cessation rates among employees at General Electric worksites throughout the United States.


Options:
A: Biochemical verification of smoking status. (15 months)
B: Expired Carbon Monoxide (Baseline and treatment phases, 2-mont and 6-month follow up.)
C: Biochemically verified smoking cessation rates at 6 months post-quit date
D: verified abstinence 6 months (6 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Financial Incentives for Smoking Cessation
Brief Summary: The purpose of this study is to test the effectiveness of financial incentives for increasing long-term smoking cessation rates among employees at General Electric worksites throughout the United States.


Options:
A: Effectiveness of a worksite intervention on physical activity behavior (12 months)
B: EQ-5D (Baseline, change in EQ-5D at 6 weeks)
C: Biochemically verified smoking cessation rates at 6 months post-quit date
D: weight loss (3 months); Weight loss (1 year)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Financial Incentives for Smoking Cessation
Brief Summary: The purpose of this study is to test the effectiveness of financial incentives for increasing long-term smoking cessation rates among employees at General Electric worksites throughout the United States.


Options:
A: Self-reported, Smoking Abstinence Rate: 6-month Prolonged Abstinence (12 months after randomization)
B: Biochemically verified smoking cessation rates at 6 months post-quit date
C: Motivation to quit smoking, utilization of available resources, smoking cessation rate (1 year)
D: Quit line re-enrollment (At 6 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The CORP Trial: COlchicine for Recurrent Pericarditis
Brief Summary: The purpose of the study is to determine whether colchicine is safe and effective in the treatment and prevention of recurrent pericarditis (first episode).


Options:
A: Recurrence rate at 18 months (18 m onths)
B: Recurrence rate at 18 months
C: Responders (24 hours after baseline)
D: Post-pericardiotomy syndrome, post-operative effusions, post-operative atrial fibrillation incidence (3 months)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Treatment and Prevention of Pericarditis With Colchicine. A Multicenter Double Blind Randomized Trial. The COPPS Trial: COlchicine for the Prevention of Postpericardiotomy Syndrome
Brief Summary: The purpose of the study is to determine whether colchicine is safe and effective in the prevention of the postpericardiotomy syndrome.


Options:
A: Responders (24 hours after baseline)
B: Post-pericardiotomy syndrome, post-operative effusions, post-operative atrial fibrillation incidence (3 months)
C: Recurrence rate at 18 months
D: Postpericardiotomy syndrome (12 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Three Dose Levels of CORLUX™ (Mifepristone) Plus an Antidepressant vs. Placebo Plus an Antidepressant in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features (PMD)
Brief Summary: Corlux (mifepristone) is a new medication that modulates the body's use of a hormone called cortisol. Under normal conditions, cortisol and other hormones are created by the body in response to physical and emotional stress, triggering a healthy stress response. People who suffer from psychotic major depression may have unusually high levels of cortisol circulating within them or abnormal patterns of cortisol levels, overloading the stress response mechanism and causing symptoms of psychosis such as delusional thoughts or hallucinations. If Corlux can keep the body's cortisol receptors from being overloaded, the stress response system may return to normal function, which may result in improvement of symptoms. The purpose of this 56 day study is to learn the safety and effectiveness of Corlux in patients who have been diagnosed with psychotic major depression (PMD).


Options:
A: Remission of Depression Hamilton Depression Scale (Ham-D) and Psychosis Schedule for Affective Disorders in Schizophrenia - Delusional Item (SADS) During the Course of the Trial (Weeks 1 to 12)
B: The change in a measure of psychosis (screening and on Days 0, 7, 14, 28, 42, and 56)
C: The change in a measure of psychosis (screen, Days 0, 7, 14, 28, 42, 56)
D: The change in a measure of psychosis (screening and on Days 0, 7, 14, 28, 42, and 56)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh
Brief Summary: The purpose of this trial is determine whether a 50,000 IU oral dose of vitamin A delivered to newborn infants within the first days of life, reduces six-month infant mortality by at least 15%. The trial will also evaluate whether the survival impact of newborn vitamin A dosing is modified by concurrent weekly, routine maternal vitamin A or beta-carotene supplementation during pregnancy through three months postpartum, gestational age and birth size.


Options:
A: Thymus size measured by ultrasound (through 15 wk of age); peripheral blood naive T-helper lymphocyte concentration (through 15 wk of age); T-cell receptor excision circle (TREC) level in peripheral blood mononuclear cells (PBMC) (through 15 wk of age); T-cell response to BCG (Bacillus Calmette-Guérin; to protect against tuberculosis) and oral polio virus (OPV) immunization (through 15 wk of age); Antibody response to oral polio virus (OPV) immunization (through 15 wk of age); T-cell and antibody response to tetanus toxoid (TT) and hepatitis B virus (HBV) vaccinations given at 6, 10 and 14 wk of age (through 15 wk of age); bacterial translocation to blood (through 15 wk of age)
B: Naïve T-cells in peripheral blood (measured once at 52 - 104 weeks of age)
C: 24-week infant mortality rate
D: intestinal parasitic infections (6 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh
Brief Summary: The purpose of this trial is determine whether a 50,000 IU oral dose of vitamin A delivered to newborn infants within the first days of life, reduces six-month infant mortality by at least 15%. The trial will also evaluate whether the survival impact of newborn vitamin A dosing is modified by concurrent weekly, routine maternal vitamin A or beta-carotene supplementation during pregnancy through three months postpartum, gestational age and birth size.


Options:
A: 24-week infant mortality rate
B: Thymus size measured by ultrasound (through 15 wk of age); peripheral blood naive T-helper lymphocyte concentration (through 15 wk of age); T-cell receptor excision circle (TREC) level in peripheral blood mononuclear cells (PBMC) (through 15 wk of age); T-cell response to BCG (Bacillus Calmette-Guérin; to protect against tuberculosis) and oral polio virus (OPV) immunization (through 15 wk of age); Antibody response to oral polio virus (OPV) immunization (through 15 wk of age); T-cell and antibody response to tetanus toxoid (TT) and hepatitis B virus (HBV) vaccinations given at 6, 10 and 14 wk of age (through 15 wk of age); bacterial translocation to blood (through 15 wk of age)
C: Primary outcome is reduction in Infant Mortality less than six months of age (2 years)
D: Risk of death (Period between receiving the intervention/placebo and six months of age)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: A Randomized Community Trial of Newborn Vitamin A Supplementation to Reduce Infant Mortality in Rural Bangladesh
Brief Summary: The purpose of this trial is determine whether a 50,000 IU oral dose of vitamin A delivered to newborn infants within the first days of life, reduces six-month infant mortality by at least 15%. The trial will also evaluate whether the survival impact of newborn vitamin A dosing is modified by concurrent weekly, routine maternal vitamin A or beta-carotene supplementation during pregnancy through three months postpartum, gestational age and birth size.


Options:
A: Mortality
B: Exclusive Breastfeeding Rates in Burkina Faso (at 3 months of age); Infant Morbidity, 2 Week Diarrhoea Prevalence (at 3 months of age); Exclusive Breastfeeding Rates in Uganda (at 3 months of age); Exclusive Breastfeeding Rates in South Africa (at 3 months of age)
C: Mortality; Morbidity
D: 24-week infant mortality rate

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Cancer Prevention Mastery Model Internet Intervention
Brief Summary: RATIONALE: An internet-based health behavior program that provides information about physical activity, fitness, and nutrition may help participants become healthier and reduce the risk of developing cancer.

PURPOSE: This randomized clinical trial is studying an individualized internet-based health behavior program to see how well it works compared to a standard internet-based health behavior program in preventing cancer and improving physical activity, fitness, and nutrition in participants who are physically inactive with a higher body mass index.


Options:
A: Body Weight (1 year)
B: N/A
C: Weight loss at 6 months
D: Change in Body Weight. (one year)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: A Double-Blind, Controlled, Randomized, Phase III Study of the Efficacy of an HPV16/18 VLP Vaccine in the Prevention of Advanced Cervical Intraepithelial Neoplasia (CIN2, CIN3, Adenocarcinoma In Situ [AIS] and Invasive Cervical Cancer) Associated With HPV 16 or HPV 18 Cervical Infection in Healthy Young Adult Women in Costa Rica.
Brief Summary: RATIONALE: Chemoprevention is the use of certain drugs to keep cancer form forming, growing, or coming back. Vaccines may help the body build an effective immune response against human papillomavirus and may be effective in preventing cervical intraepithelial neoplasia or cervical cancer. It is not yet known whether human papillomavirus vaccine is more effective than hepatitis A vaccine in preventing cervical intraepithelial neoplasia or cervical cancer.

PURPOSE: This randomized phase III trial is studying human papillomavirus vaccine to see how well it works compared to hepatitis A vaccine in preventing cervical intraepithelial neoplasia or cervical cancer in younger healthy participants.


Options:
A: Number of Seroconverted Subjects for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies in Cervarix 1 Group and Cervarix 2 Group at Month 7 (At Month 7 (i.e. one month after the last dose of study vaccine)); Anti-HPV-16 and Anti-HPV-18 Antibody Concentrations (by ELISA) in Cervarix 1 Group and Cervarix 2 Group at Month 7 (At Month 7 (i.e. one month after the last dose of study vaccine))
B: Number of Seroconverted Subjects for Anti-HPV-16 and Anti-HPV-18 (At Month 7); Antibody Titers Against HPV-16 (Anti-HPV-16) and HPV-18 (Anti-HPV-18) (At Month 7)
C: Occurrence of intraepithelial neoplasia grade 3 or worse (CIN3+). including CIN3, cervical cancer (squamous cell carcinoma or adenocarcinoma). (The time frame is up to 15 years (for the interim analyses: 4, 7 and 10 years). (Start and end of passive follow-up, Cohorts A and B: 01.01.2010 - 31.12. 2024; Cohorts C1 and C2: 01.10.2007/01.10.2008 - 30.09.2021/30.09.2023.))
D: Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical Cytology Specimen. (From Month 6 up to Month 48)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Improving Coronary Prevention in a County Health System
Brief Summary: To examine whether the Stanford Health Education and Risk Reduction Training (HEAR2T) program , a case management approach, can be effectively used to manage the risk of coronary artery disease.


Options:
A: Rate of use of the three home-based technologies (3-months)
B: Mortality (From diabetes diagnosis until median14 year after study start); Diabetic retinopathy (at 6 year and 14 year after study start); Urinary albumin concentration (at 6 year and 14 year after study start); Myocardial infarction (From diabetes diagnosis until median14 year after study start); Stroke (From diabetes diagnosis until median14 year after study start)
C: HbA1c (3 months)
D: Framingham Risk Score (15 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Improving Coronary Prevention in a County Health System
Brief Summary: To examine whether the Stanford Health Education and Risk Reduction Training (HEAR2T) program , a case management approach, can be effectively used to manage the risk of coronary artery disease.


Options:
A: Composite endpoint death and cardiovascular events (1-year after randomization); Hospitalization (1-year after randomization); Composite endpoint death and broader cardiovascular events (1-year after randomization)
B: Change in proportion of patients taking oral anticoagulants (1 year)
C: Death (4 months); Death (8 months); Death (12 months); Death (16 months); Death (20 months); Death (24 months); Death (3 years); Death (4 years); Stroke/Systemic embolism (SE) (4 months); Stroke/Systemic embolism (SE) (8 months); Stroke/Systemic embolism (SE) (12 months); Stroke/Systemic embolism (SE) (16 months); Stroke/Systemic embolism (SE) (20 months); Stroke/Systemic embolism (SE) (24 months); Stroke/Systemic embolism (SE) (3 years); Stroke/Systemic embolism (SE) (4 years); Major bleeding (4 months); Major bleeding (8 months); Major bleeding (12 months); Major bleeding (16 months); Major bleeding (20 months); Major bleeding (24 months); Major bleeding (3 years); Major bleeding (4 years)
D: Framingham Risk Score (15 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Improving Coronary Prevention in a County Health System
Brief Summary: To examine whether the Stanford Health Education and Risk Reduction Training (HEAR2T) program , a case management approach, can be effectively used to manage the risk of coronary artery disease.


Options:
A: The proportion of high-risk individuals that have been assessed for cardiovascular risk (12 months after intevention); The proportion of individuals with correct knowledge about the effects of behavioural determinants of the risk of cardiovascular disease (12 months from intervention)
B: Change in Systolic Blood Pressure (baseline and 6 months); Change in HDL Level (baseline and 6 months); Change in LDL Level (baseline and 6 months); Change in Triglyceride Level (baseline and 6 months); Change in HbA1c Level (baseline and 6 months); Change in Glycaemia Level (baseline and 6 months); Change in BMI Value (baseline and 6 months)
C: Change Between the Value of the SF-36 Physical Function Score at 12 Months Minus Value at Baseline to Measure the Change in Health-related Quality of Life and Function (Baseline (pre-randomization) and 12 months)
D: Framingham Risk Score (15 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Improving Coronary Prevention in a County Health System
Brief Summary: To examine whether the Stanford Health Education and Risk Reduction Training (HEAR2T) program , a case management approach, can be effectively used to manage the risk of coronary artery disease.


Options:
A: Physical activity (4 years); Modelled cardiovascular risk (4 years); Health related quality of life (4 years); Functional capacity (4 years)
B: Mean change in systolic Blood Pressure (BP) (Baseline to 12 months)
C: The comparison of change in vascular monitoring process total score (proportion of process targets met in group) between intervention and control groups. (6 months to 1 year)
D: Framingham Risk Score (15 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Improving Coronary Prevention in a County Health System
Brief Summary: To examine whether the Stanford Health Education and Risk Reduction Training (HEAR2T) program , a case management approach, can be effectively used to manage the risk of coronary artery disease.


Options:
A: Changes in anthropometry (BMI, waist and hip cf) (3 years); Maximal oxygen uptake (VO2max) (3 years); Health-related quality of life (EQ 5D, SF-36) (3 years); Self-reported physical activity (3 years)
B: weight change at 18 months (18 months)
C: Body Mass Index (Baseline, 3-, 6- and 15- month follow-up)
D: Framingham Risk Score (15 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Determination of the Optimal Prophylactic Platelet Dose Strategy to Prevent Bleeding in Thrombocytopenic Patients (A TMH CTN Study)
Brief Summary: The primary objective of this study is to compare the three study arms of lower, medium, and higher dose platelet therapy with respect to the percentage of patients experiencing at least one episode of Grade 2 or higher bleeding as determined by the Platelet Dose Trial Bleeding Scale (Grade 2 bleeding corresponds to bleeding that is moderate, but not severe enough to warrant red blood cell transfusion).

There are a number of secondary endpoints related to platelet transfusions, hemostasis, and other concerns. The four most important secondary endpoints will compare the three study arms with respect to the following outcomes: 1) platelet utilization rates (total number of platelets transfused x 10 \^11); 2) number of platelet transfusion events (frequency of transfusions); a transfusion event would be defined as each separate platelet transfusion issued by the study site's transfusion service; 3) highest category of bleeding during time of study (Platelet Dose Trial Bleeding Scale Grades less than or equal to 1, 2, 3, or 4 by arm); and 4) bleeding severity based on number of days with bleeding (total days of bleeding and bleeding/thrombocytopenic day), intensity of bleeding, and number of sites with bleeding (if such a severity score has been validated and published by the time the study is completed).


Options:
A: Bleeding within 24 hours after cvc application; other complications within the first 24 hours
B: At Least One Day With Grade 2 or Higher Bleeding (From randomization until the subject ends the study (10 days after most recent platelet transfusion, 30 days after first platelet transfusion on study, or hospital discharge, whichever occurs first))
C: reduction in numbers of platelet transfusion by 25 % in the experimental arm (therapeutic transfusion strategy)compared with the standard arm (prophylactic transfusion strategy) (2010)
D: Daily hemostatic assessments will be conducted to determine presence of WHO Grade 2 bleeding or greater.

Answer: B